A detailed history of Vanguard Group Inc transactions in Altimmune, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,983,858 shares of ALT stock, worth $40.1 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,983,858
Previous 4,906,614 1.57%
Holding current value
$40.1 Million
Previous $32.6 Million 6.22%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$5.5 - $8.1 $424,842 - $625,676
77,244 Added 1.57%
4,983,858 $30.6 Million
Q2 2024

Aug 13, 2024

BUY
$5.91 - $10.23 $10.5 Million - $18.2 Million
1,777,886 Added 56.82%
4,906,614 $32.6 Million
Q1 2024

May 10, 2024

SELL
$8.22 - $13.81 $3.64 Million - $6.12 Million
-443,244 Reduced 12.41%
3,128,728 $31.9 Million
Q4 2023

Feb 14, 2024

BUY
$2.14 - $11.62 $487,228 - $2.65 Million
227,677 Added 6.81%
3,571,972 $40.2 Million
Q3 2023

Nov 14, 2023

BUY
$2.4 - $3.45 $91,975 - $132,214
38,323 Added 1.16%
3,344,295 $8.7 Million
Q2 2023

Aug 14, 2023

BUY
$3.45 - $5.97 $2.65 Million - $4.59 Million
768,251 Added 30.27%
3,305,972 $11.7 Million
Q1 2023

May 15, 2023

BUY
$4.19 - $16.83 $22,211 - $89,215
5,301 Added 0.21%
2,537,721 $10.7 Million
Q4 2022

Feb 10, 2023

BUY
$8.74 - $16.45 $4.42 Million - $8.31 Million
505,378 Added 24.93%
2,532,420 $41.7 Million
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $3.22 Million - $6.76 Million
301,496 Added 17.47%
2,027,042 $25.9 Million
Q2 2022

Aug 12, 2022

SELL
$3.94 - $11.77 $359,993 - $1.08 Million
-91,369 Reduced 5.03%
1,725,546 $20.2 Million
Q1 2022

May 13, 2022

BUY
$5.9 - $9.45 $490,644 - $785,861
83,160 Added 4.8%
1,816,915 $11.1 Million
Q4 2021

Feb 14, 2022

BUY
$8.69 - $12.48 $846,388 - $1.22 Million
97,398 Added 5.95%
1,733,755 $15.9 Million
Q3 2021

Nov 12, 2021

BUY
$8.43 - $16.81 $423,725 - $844,937
50,264 Added 3.17%
1,636,357 $18.5 Million
Q2 2021

Aug 13, 2021

BUY
$9.85 - $16.46 $15.6 Million - $26.1 Million
1,586,093 New
1,586,093 $15.6 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $395M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.